A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Recruiting now · Phase 2

Conditions studied: Ulcerative Colitis

In brief

Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years. Participants visit their doctors every 4 weeks. During these visits, the doctors check the signs and symptoms of ulcerative colitis. This includes taking blood and stool samples. Doctors also do endoscopies. This is a procedure that uses a tube with a camera to look inside the body. The doctors also regularly check participants' health and take note of any unwanted effects.

Key facts

Study ID

NCT06636656

Run by

Boehringer Ingelheim

People needed

80

Starts

2024-12-11

Expected to finish

2029-07-30

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Female and male participants aged 18 to 80 years (inclusive) at the time of informed consent,
• Diagnosis of ulcerative colitis (UC) ≥3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report,
• Inadequate response, loss of response, or intolerance to treatment with biologic/targeted therapy or termination of treatment with biologic/targeted therapy for any other reason,
• Female participants of childbearing potential must be ready and able to use highly effective methods of birth control and male participants are required to use condoms,
• Further inclusion criteria apply.

You may not qualify if…

• Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis, or Crohn's disease (CD),
• Findings suggestive of CD (e.g. fistulae, granulomas on biopsy),
• Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed,
• Gastrointestinal neoplasia, primary sclerosing cholangitis, or known colonic stricture,
• Evidence of fulminant colitis or toxic megacolon at screening,
• Current ileal-pouch anal anastomosis, ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine,
• Previous surgery or anticipated surgical intervention for UC (trial participants with previous colonic surgery may be allowed based on investigator's judgement after discussion with the sponsor),
• Any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to first trial drug administration and are not anticipated to require surgery,
• Further exclusion criteria apply.

Where it is running

• EMC Instytut Medyczny S.A. - Wroclaw — Wroclaw, Poland (enrolling)
• Peak Gastroenterology Associates — Colorado Springs, Colorado, United States (enrolling)
• Pro Life Medica Sp. z o.o. — Zamość, Poland (enrolling)
• Clinical Hospital Center Zvezdara — Belgrade, Serbia (enrolling)
• General Hospital - Djordje Joanovic — Zrenjanin, Serbia (enrolling)
• F D Roosevelt University General Hospital Of Banska Bystrica — Banská Bystrica, Slovakia (enrolling)
• ENDOMED s.r.o. — Košice, Slovakia (enrolling)
• KM Management, spol. s.r.o. — Nitra, Slovakia (enrolling)
• Gastro I., s.r.o — Prešov, Slovakia (enrolling)
• Florida Research Institute — Lakewood Rch, Florida, United States (enrolling)
• University of Miami — Miami, Florida, United States (enrolling)
• Reliant Medical Research — Miami, Florida, United States (enrolling)
• Illinois Gastroenterology Group - Gurnee — Gurnee, Illinois, United States (enrolling)
• University of Kansas Medical Center — Kansas City, Kansas, United States (enrolling)
• Atrium Health Gastroenterology and Hepatology — Charlotte, North Carolina, United States (enrolling)
• Texas Digestive Disease Consultants — Cedar Park, Texas, United States (enrolling)
• Baylor College of Medicine — Houston, Texas, United States (enrolling)
• Digestive Health Specialists — Tacoma, Washington, United States (enrolling)
• UZ Leuven — Leuven, Belgium (enrolling)
• CHC MontLegia — Liège, Belgium (enrolling)
• ISCARE a.s. — Prague, Czechia (enrolling)
• Centrum Medyczne Plejady — Krakow, Poland (enrolling)
• Medrise Sp. z o.o. — Lublin, Poland (enrolling)
• Eskulap Pabianice Sp. z o.o. — Pabianice, Poland (enrolling)
• EMC Instytut Medyczny S.A. - Poznan 70-304 — Poznan, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.